Dr. He is an associate professor from the Department of Pharmaceutics, College of Pharmacy at the University of Florida. She obtained her PhD degree from the University of Alberta and postdoc training from the University of California, Berkeley. Dr. He is the Editorial Board member of Pharmaceutics and AAPS Scientific Programming Committee Track Leader, as well as the Advisory Board Member of journal Lab on Chip (LOC). Her journal review efforts have been recognized as the Outstanding Reviewers in 2018, 2020, and 2021 from the LOC Royal Society of Chemistry. Dr. He Received NIH Maximizing Investigator’s Research Award for Early Stage Investigators in 2019, and she also received the LOC Emerging Investigator Award in 2019. Her multiple publications received the Most Download Articles of 2016 (LOC), the Featured Cover Story of 2018 (LOC), Technology Readers Choice Award of 2018 (SLAS), and Top 100 Read Articles of 2019 (Scientific Reports from Nature Publishing Group). Her recent publication is appeared in the journal of Nature Biomedical Engineering and highlighted as the Editorial Story. Dr. He research brings in novel technology platforms for differentiating, isolating, and intravesicular loading exosomes precisely, which presents a new way for developing precision medicine Dr. He’s innovation leads to 17 pending and issued patents and have been licensed by multiple companies and commercialized on the market. Particularly, she founded a few startup companies for advancing the innovative exosome research.

The vision and aim of the Möller lab is to improve cancer patient’s outcome by leveraging on my innovative findings to develop novel solutions for currently unmet clinical needs. Professor Andreas Möller is a trained biochemist and cancer biologist, with >20 years’ experience in cancer research. He is Professor in the Faculty of Medicine at the Chinese University of Hong Kong, supported by a highly competitive and prestigious Global STEM Professor fellowship. Prof Möller is also the Director of the Jockey Club Laboratory of Precision Cancer Medicine at the Li Ka Shing Institute of Health Sciences, supported by peer-reviewed governmental, philanthropic and industry funding. He also holds an Honorary Group Leader position for the Tumour Microenvironment Laboratory at the QIMR Berghofer (QIMRB) since 2023. Previously, between 2012 and 2023, he led the QIMRB Tumour Microenvironment Laboratory as Faculty member and Group Leader. Prof Möller has a strong background in cancer cell biology, extracellular vesicle (EV) biology, hypoxia research, cancer metastasis and cancer immunology. His research program develops novel approaches to understand cancer metastasis, and how the composition of the tumor microenvironment is coordinated, with the aim and focus of translating the findings into clinical and commercial applications. He is an internationally recognized expert in cancer metastasis, EVs and cancer immune responses, evidenced by being in the top 0.015% of researchers (FWCI >19) in Extracellular Vesicles topic (SciVal), and top 1% in five topics, including myeloid cells in the tumor microenvironment and myeloid-derived suppressor cells. Since the inception of his group in 2012, he has published over 80 articles, and is corresponding author on >50% of these papers. He developed intellectual property based on the finding that a blood-based EV protein signature can identify cancer early and prognosticate outcomes with high accuracy, and collaborates with several commercial partners who licensed those patent families to implement these inventions. He has received over US$15 million in research grants from international and national sources as PI, and successfully supervised 13 Honors and 10 PhD students to completion. He is Member of the Board of Directors of the International Society of Extracellular Vesicles since 2022, and since 2024 elected Executive Chairs for Meetings and Programs. Prof Möller is founding Director and Executive Board Member of the Asia Pacific Societies of Extracellular Vesicles.

Sven Kreutel studied biology at the University of Hohenheim in Stuttgart, Germany. After his graduation in biology, he received his PhD in microbiology and protein biochemistry at the University of Hohenheim under Prof. Dr. Andreas Kuhn and Dr. Dorothee Kiefer working on the light sensing and signal transduction in photosynthetic bacteria. Since then he worked in different sales and sales manager positions within the life science industry from clinical research over biology to nanoparticle sciences. In 2021 he was appointed as CEO of the American subsidiary of Particle Metrix.